Asia-Pacific Contraceptive Drugs and Devices Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

1. INTRODUCTION

• 1.1 Study Deliverables
• 1.2 Study Assumptions
• 1.3 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Incidence of the STDs
  • 4.2.2 Increasing Rate of Unintended Pregnancies
  • 4.2.3 Rise in Government Initiatives
• 4.3 Market Restraints
  • 4.3.1 High Cost of Devices and Treatment
  • 4.3.2 Side Effects Associated with the Use of Contraceptive Drugs and Devices
• 4.4 Porter's Five Forces Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION

• 5.1 By Product
  • 5.1.1 By Drugs
  • 5.1.1.1 Oral Contraceptives
  • 5.1.1.2 Topical Contraceptives
  • 5.1.1.3 Contraceptive Injectable
  • 5.1.2 By Device
  • 5.1.2.1 Condoms
  • 5.1.2.2 Diaphragms
  • 5.1.2.3 Cervical Caps
  • 5.1.2.4 Sponges
  • 5.1.2.5 Vaginal Rings
  • 5.1.2.6 IUD
  • 5.1.2.7 Other Devices
• 5.2 By Gender
  • 5.2.1 Male
  • 5.2.2 Female
• 5.3 Geography
  • 5.3.1 Asia-Pacific
  • 5.3.1.1 China
  • 5.3.1.2 Japan
  • 5.3.1.3 India
  • 5.3.1.4 Australia
  • 5.3.1.5 South korea
  • 5.3.1.6 Rest of Asia-Pacific

6. COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Bayer AG
  • 6.1.2 Pfizer Inc.
  • 6.1.3 Merck & Co. Inc.
  • 6.1.4 CooperSurgical Inc.
  • 6.1.5 Allergan PLC
  • 6.1.6 Johnson & Johnson Ltd
  • 6.1.7 Lupin Pharmaceuticals Ltd
  • 6.1.8 Mylan Laboratories
  • 6.1.9 Church & Dwight Co. Inc.
  • 6.1.10 The Female Health Company
• *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS